MARKET ACCESS RADAR
MARKET ACCESS DATABASE & REPOSITORY

SUPPORTING EFFICIENT PRICING & REIMBURSEMENT (P&R) WORKFLOWS
BY PHARMA MARKET ACCESS DATABASE & REPOSITORY

Market Access Radar (MAR)

Market Access Radar (MAR) is a pharma market access database and repository of more than 8 years with daily delivery of the most up-to-date Market-Access (MA) related news and reports, hand-picked by experts in reimbursement. The service is available as an online repository (**marketaccess-radar.com**) with search engines (integrated with MeSH terms) and advanced user profiles which enable customized data flow under user specifications, including country/category filters, tags, and daily or weekly reports.

MAR was created to provide quick and easy access to the most important MA-related information, featuring an easy-to-follow layout to bring the most relevant data directly to you. We gather the latest reimbursement recommendations, information on financing from public funds announced by Ministries of Health (MOH) and Health Technology Assessment (HTA) agencies, and changes in legal provisions regulating the financing of health technologies from public funds.

38,000
RECORDS

Compliant, Integrated P&R Records

SPEND TIME ON YOUR P&R STRATEGY, NOT SEARCHING FOR RELEVANT INFORMATION.

600 Market-Access-Related sources of information from all over the world

MOH and HTA Agencies
Latest reimbursement recommendations and information on financing from public funds announced by Ministries of Health and Health Technology Assessment agencies.

Law and P&R
Information on changes in legal provisions regulating financing of health technologies from public funds.

And More
News on drug safety, new marketing authorizations, variations in registered and reimbursed indications published by EMA, HMA, FDA, MHRA, Ministries of Health and other national institutions responsible for registration and safety of drugs and other valuable information which may impact reimbursement, published in mass media and relevant press.

50 countries covered with a Central & Eastern European local experts network

MAR combines the assistance of local MA experts with web monitoring. MAR collaborates with rooted experts, who assess and prepare relevant data daily. This ensures that users receive MA-related information of the highest quality and importance. The MAR team gathers data from over 50 countries. If a user needs more information about the given record, either concerning the local market or due to the need for additional analysis, the user can click "Ask the Expert" for a question about the selected topic. This is available for each record.

2,280
DAILY REPORTS IN MAR ARCHIVE

CUSTOMIZE YOUR REPOSITORY

10

User profiles to customize your repository

EDIT PROFILE 2   CLEAR

**Lung Cancer**
REGIONS: EUROPE
OTHER lung cancer, advanced lung cancer, advanced non-small cell lung cancer, ALK-positive advanced non-small-cell lung cancer, metastatic non-small cell lung cancer , non small cell lung cancer
SOURCES: Companies, Media, Agency, Chambers, MoH/Gov/Payer, Other

EDIT PROFILE 1   CLEAR

Migraine
REGIONS: EUROPE, CEE, CIS AND BALTIC, AMERICA, ASIA AND AUSTRALIA, GLOBAL
OTHER Acute Migraine
SOURCES: Companies, Media, Agency, Chambers, MoH/Gov/Payer, Other

A user can set up 10 different My Radar profiles, switch between profiles by clicking the "My Radar" button, and customize each profile. Enter your country(ies) of interest (dropdown selection available) or select an entire region. You can mix both: e.g., Europe as the region and U.S. as the country. Enter "Your Interests", the information you would like to receive on My Radar substances, brands, indications, agency names, etc. Customize based on existing tags in the repository. Advanced settings are based on close relationships between three values: indication, brand, and substance. As a result of the monitoring, you will receive information if there is an association with a brand or substance in the database for a particular indication (e.g., drug evaluation process by NICE or HAS). The user does not need to enter advanced settings and can rely only on the field in "Your Interests", which has a wider results scope.

Streamline P&R data management and analysis

REPORT SETTINGS

Receive report daily or weekly by email

	DAILY	WEEKLY	NEVER
Migraine		● WEEKLY	
Lung Cancer Poland & Germany		● WEEKLY	
waldenstrom macroglobulinemia		● WEEKLY	
USA & Canada news	● DAILY		
DEFAULT	● DAILY		

The user can also create the content of the report, which will consistently show only the customized information based on the user's profiles. If the user does not create unique profiles, MAR will send records (as default) added to the database on a given day or week.

Using our integrated platform, effortlessly share information across your organization via a secure and consistent workflow.

10 KEY VALUES

600
Market-access-related sources of information from all over the world

All the records you need
In a single, interoperable repository with a tag system and search engine

Ask a local expert
Receive further details with a short analysis from our local experts at any time during use

Records selected manually
Records prepared manually by local experts with years of experience in the MA field

Multiple countries in one language
There is no need to translate from the local language to obtain information
(all records in English)

Fast access
User has access to a quick overview of data in the Dashboard, My Radar, and Daily Brief

Customization
Create up to 10 different user profiles to tailor your MAR

Results export
Quick and easy export of search results and profiles from reports

Track brands/substances/indication
Track brands/substances/indication specific to your needs

Tailor your reports
Determine what you receive in your reports and when you receive them

MARKET ACCESS RADAR
MARKET ACCESS DATABASE & REPOSITORY

See more about Market Access Radar on:
marketaccess-radar.com

or

Contact us directly:
contact@marketaccess-radar.com

contact@marketaccess-radar.com

About Certara

Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

For more information, visit **www.certara.com**.